Tempus AI
TEMTEM · Stock Price
Historical price data
Overview
Tempus AI is a public technology company with a mission to enable data-driven, personalized medicine through its proprietary AI platform and massive, structured real-world data library. Its core strategy involves a virtuous cycle: generating revenue through clinical testing and data/analytics services for providers and life sciences companies, while using that same data flow to fuel internal therapeutic discovery and enhance its platform's predictive power. Key achievements include establishing a dominant data network with over 65% of U.S. academic medical centers, securing multiple FDA clearances for its diagnostic assays, building a pipeline of seven internal drug candidates, and being selected for strategic government partnerships like the ARPA-H ADAPT program.
Technology Platform
An integrated AI-powered operating system that aggregates, structures, and analyzes multimodal clinical and molecular data (genomics, pathology, radiology, clinical notes) to generate insights for clinical decision support, drug development, and therapeutic discovery.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Pegylated interferon alpha 2 + Ribavirin | Hepatitis C | Approved | |
| Pegylated IFN- alpha 2b + Ribavirin | Hepatitis C | Approved | |
| Targeted Therapy Based on Molecular Profiling + Standard-of-... | Metastatic Malignant Neoplasm | Phase 2 | |
| Niraparib | Solid Tumor | Phase 2 | |
| A2B694 + A2B543 | Solid Tumor, Adult | Phase 1/2 |
Funding History
4Company Timeline
IPO — $410.0M
Series I: $200.0M
Series H: $200.0M